UK Markets closed
  • FTSE 100

    +4.04 (+0.05%)
  • FTSE 250

    +119.88 (+0.60%)
  • AIM

    +3.83 (+0.44%)

    +0.0015 (+0.13%)

    -0.0012 (-0.0967%)

    -99.69 (-0.53%)
  • CMC Crypto 200

    +9.65 (+1.87%)
  • S&P 500

    +10.13 (+0.25%)
  • DOW

    +28.67 (+0.08%)

    -1.63 (-2.01%)

    -2.80 (-0.14%)
  • NIKKEI 225

    +19.81 (+0.07%)

    +122.12 (+0.54%)
  • DAX

    +17.18 (+0.11%)
  • CAC 40

    +1.22 (+0.02%)

Dry Eye Syndrome Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2018-2028


Summary. Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface.

New York, Jan. 20, 2023 (GLOBE NEWSWIRE) -- announces the release of the report "Dry Eye Syndrome Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2018-2028" -
The DES market has had few new therapeutics in the last decade.

However, the current treatment landscape is anticipated to witness a dramatic progress with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 7MM.

Anticipated to be a lucrative market given that its prevalence is expected to increase during the forecast period as well as a significant need to introduce new therapy options for the indication. Therefore, the trend of strategic deals in DES is expected to increase during the forecast period as more late-stage pipeline products are anticipated to enter the market during this period.

New pipeline products will help in addressing clinical unmet needs such as need for more therapies. Environmental unmet needs such as need for better diagnostic tools and appropriate clinical trials design are anticipated to be addressed by a combination of the field progressing in terms of disease understanding and product innovations.

Key Highlights
- The DES market is expected to witness a CAGR of 11.3% from 2018 to 2028, reaching global value of $10.0 billion.
- the analyst anticipates that 11 pipeline drugs will launch over the forecast period and all of them in the US market. A small proportion of these products are based on known MOAs such as cyclosporine-based formulations, while the other products are based on novel MOAs.
- While clinical unmet needs such as need for more treatment options are expected to be met by launch of pipeline products in the forecast period, environmental unmet needs such as those for better diagnostic tools are expected to be addressed by a combination of new product launches and improvement in understanding of the disease pathology.
- There is also an anticipation that as more pipeline therapies move into the critical stages of late-stage development and pre-approvals, some of these companies with particularly promising therapy for DES may enter into some form of strategic partnerships with other companies in order to maximize the potential of commercial success of these products.

Key Questions Answered
- What are the key unmet needs in DES? Will the products in the current pipeline fill these unmet needs?
- When will the late stage pipeline products launch, and how will it affect drug sales and the overall DES market in the 7MM?

- Overview of DES, including epidemiology, pathophysiology, diagnosis, and disease management.
- Market Data including annualized DES therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in different patient segments (mild, moderate, severe) forecast from 2018 to 2028.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DES therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DES therapy. The most promising candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global DES therapeutics market: Insightful review of the key industry drivers and barriers. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global DES therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DES therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001